Dialog Box

Loading...

Clinical Trials

 

Current Trials Open to Recruitment |

How do I become involved in a clinical trial? 

  

 

The Skin & Cancer Foundation Inc.'s Clinical Trials Department has been involved in over 100 clinical trials in the last 30 years. Many of these trials have led to life-changing treatments used for a wide range of conditions including skin cancer, psoriasis and rosacea.

 

The research activities of the Clinical Trials Department are supervised and coordinated by specialist dermatologist, Associate Professor Peter Foley, assisted by Associate Professor Chris Baker, Associate Professor Alvin Chong and Dr Maree Micallef.

Learn more about the Clinical Trials Team

 

Successful treatments approved for use in Australia, which were tested by our Clinical Trials Department include:

 

Drug/Treatment  Condition 
Aldara  Basal cell carcinoma; Actinic Keratosis 
PDT Metvix & Daylight PDT  Actinic Keratosis; Superficial basal cell carcinoma 
Humira  Psoriasis; Hidradenitis suppurativa 
Soolantra  Rosacea 
Enbrel  Psoriasis; Psoriatic Arthritis 
Picato  Actinic Keratosis 
Cosentyx Psoriasis 
Tremfya Psoriasis 
 IIlumya Psoriasis
 Erivedge Advanced Basal Cell Carcinoma
 Dupixent Atopic Dermatitis
 Elidel Atopic Dermatitis
 Stelara Psoriasis
 Taltz Psoriasis
 

Current Clinical Trials Now Recruiting 

 

If you would like to learn more about any of the studies currently being conducted at the Skin & Cancer Foundation Inc, please contact the nominated study coordinator.

 

If you have any general questions regarding the clinical trials conducted at the Foundation, please feel free to contact the Clinical Trials Department at trials@skincancer.asn.au

 

52 WEEK PLAQUE PSORIASIS RESEARCH STUDY 

(60 weeks in total including screening and follow up)

 

Men and women aged 18 years or older, with stable plaque psoriasis for 6 months or more, may qualify to receive investigational  medication (active drug), placebo and/or active comparator.

To be eligible, participants must have plaque psoriasis that covers 10% or more of their body surface area (or an area equal to 10 hand-  sized patches). Moderate to severe disease must be present at the time of study entry. Qualified participants will have regular visits with  an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses. Individuals  will be asked to visit the study centre about 18 times over a period of up to 60 weeks. For more information, please contact:

 

Principal Investigator:
A/Prof Peter Foley

 

Sub Investigator:
Dr Natalie Wong
t: 9623 9400
e: nwong@skincancer.asn.au

Trials Manager:
Sarah Chivers
t: 9623 9465
e: schivers@skincancer.asn.au

 

 

 

CHRONIC ECZEMA RESEARCH STUDY (74 Weeks)

Adults aged 18 to 75 with a clinical diagnosis of chronic atopic dermatitis (eczema) for at least 2 years, may qualify to receive investigational medication (either active study drug or placebo).

To be eligible, participants must have atopic dermatitis involving 10% or more of their body surface area (or an area equal to 10 palm-sized patches). Moderate to severe disease severity must be present at the time of study entry. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for reasonable travel expenses.

Individuals will be asked to visit the study centre about 30 times over a period of about 74 weeks.

For more information, please contact:

 

Principal Investigator:
A/Prof Peter Foley


Sub Investigator:
Dr Natalie Wong
t: 9623 9400
e: nwong@skincancer.asn.au


Study Coordinator:
Jennifer Kaiser
t: 9623 9420
e: jkaiser@skincancer.asn.au

 

 

ECZEMA TRIAL TESTING ORAL MEDICATION

Adults aged 18 years or older with eczema (atopic dermatitis) for at least 1 year, may qualify to receive investigational oral medication (active study drug), an active comparator via injection or placebo.

To be eligible, participants must have eczema involving 10% or more of their body surface area (or an area equal to 10 palm-sized patches). Moderate to severe disease severity must be present at the time of study entry. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

Individuals will be asked to visit the study centre about 10 times over a period of about 28 weeks. For more information, please contact:

 

Study contact details:

Principal Investigator:
A/Prof Peter Foley

Sub Investigator:
Dr Natalie Wong
t: 9623 9400
e:
nwong@skincancer.asn.au

Clinical Trial Manager:
Sarah Chivers
t: 9623 9465
e:
schivers@skincancer.asn.au

 

 

TOPICAL ECZEMA RESEARCH STUDY (14 Weeks)

 

Men and women aged 18 years or older with a history of eczema (atopic dermatitis) for at least 1 year, may qualify to receive investigational topical medication (active drug) or placebo.   

To be eligible, participants must have atopic dermatitis involving 5-50% of their body surface area (or an area equal to 5-50 palm-sized patches).  Mild to severe disease severity must be present at the time of study entry. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

 

Individuals will be asked to visit the study centre about 8 times over a period of about 14 weeks.


For more information, please contact:

 

Principal Investigator:
A/Prof Peter Foley

 

Sub Investigator:
Dr Natalie Wong
t: 9623 9400
e: nwong@skincancer.asn.au

 

Study Coordinator:
Tracy Mallett
t: 9623 9406
e: tmallett@skincancer.asn.au

 

 

 

2 YEAR ECZEMA (ATOPIC DERMATITIS) RESEARCH STUDY 

 

Men and women aged 18 years or older, diagnosed with atopic dermatitis (eczema) for at least 12 months, may qualify to receive investigational oral medication. During Treatment Period 1, all participants will receive active drug. During Treatment Period 2, participants may receive active drug or placebo.

 

To be eligible, participants must have eczema that covers 10% or more of their body surface area (or an area equal to 10 palm-sized patches). Moderate to severe disease must be present at the time of study entry. Qualified participants will have regular visits with an experienced research team. There is no cost to participate, and participants will be reimbursed for study-related expenses.

 

Individuals will be asked to visit the study centre about 18 times over a period of about 2 years.

 

For more information, please contact:

 

Principal Investigator:


A/Prof Peter Foley

 

Sub Investigator:
Dr Natalie Wong
t: 9623 9400
e: nwong@skincancer.asn.au

 

Study Coordinator:
Charlotte Harrison-Mullan
t: 9623 9470
e: charrison@skincancer.asn.au


How do I become involved in a clinical trial at the Foundation?

 

Anyone wishing to participate in a clinical trial may potentially be eligible. A referral from a clinical is not necessary.

 

Contact the Clinical Trials Department directly to enquire about current research projects to determine your suitability. 

 

Phone: (03) 9623 9416

Email: trials@skincancer.asn.au

 

 

Back to top 

 

Support Our Research
Thank you for helping the Skin & Cancer Foundation continue its groundbreaking research in to skin cancer and health!
Stay In Touch
Email address is required.
Submit